{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:08:54Z","timestamp":1790788134027,"version":"4.1.0"},"reference-count":28,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Treatment algorithms for type 2 diabetes recommend weight loss for disease management. The safety and efficacy of treatment with phentermine (PHEN)\/topiramate (TPM) extended release (ER) plus lifestyle modification for weight loss and glycemic benefits were assessed in two randomized, double-blind, placebo-controlled 56-week studies of obese\/overweight adults with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>The OB-202\/DM-230 Study was a 56-week phase 2 trial that randomized subjects to receive once-daily placebo or PHEN\/TPM ER 15 mg\/92 mg (15\/92). The primary end point was change in HbA1c level. A post hoc analysis of a subpopulation with type 2 diabetes from a second study, CONQUER, is also presented. All subjects made lifestyle modifications, and comorbidities were managed to the standard of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The study groups comprised 130 subjects with type 2 diabetes enrolled in the OB-202\/DM-230 Study (mean baseline HbA1c 8.7% [72 mmol\/mol]) and 388 subjects with type 2 diabetes in the CONQUER Study (mean baseline HbA1c 6.8% [51 mmol\/mol]). At week 56 in the OB-202\/DM-230, change in weight (from intent-to-treat sample with last observation carried forward [ITT-LOCF]) was \u22122.7% for placebo and \u22129.4% for PHEN\/TPM ER 15\/92 (P &amp;lt; 0.0001 vs. placebo). Change in HbA1c level (from ITT-LOCF) was \u22121.2% (\u221213.1 mmol\/mol) for placebo and \u22121.6% (\u221217.5 mmol\/mol) for PHEN\/TPM ER 15\/92 (P = 0.0381). In both the OB-202\/DM-230 and CONQUER, greater numbers of patients randomized to receive PHEN\/TPM ER treatment achieved HbA1c targets with reduced need for diabetic medications when compared with the placebo group. Common adverse events included paraesthesia, constipation, and insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>PHEN\/TPM ER plus lifestyle modification can effectively promote weight loss and improve glycemic control as a treatment approach in obese\/overweight patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc14-0930","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T01:38:27Z","timestamp":1411522707000},"page":"3309-3316","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":137,"title":["Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release"],"prefix":"10.2337","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct00600067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00553787","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"W. Timothy","family":"Garvey","sequence":"first","affiliation":[{"name":"Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL"},{"name":"Birmingham VA Medical Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.V.","family":"Bohannon","sequence":"additional","affiliation":[{"name":"Monteagle Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Kushner","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Rueger","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman V.","family":"Dvorak","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Mountain View, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Troupin","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Mountain View, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"2022031220273979900_B1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/EP13176.CSUPPL","article-title":"AACE comprehensive diabetes management algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"key":"2022031220273979900_B3","first-page":"433","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume-title":"Circulation","author":"Grundy","year":"2004"},{"key":"2022031220273979900_B4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0026-0495(90)90299-R","article-title":"UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group","volume":"39","author":"UK Prospective Diabetes Study 7","year":"1990","journal-title":"Metabolism"},{"key":"2022031220273979900_B5","first-page":"S10","article-title":"The benefits of modest weight loss in type II diabetes","volume":"21","author":"Bosello","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031220273979900_B6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B7","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial","volume":"170","author":"Wing","year":"2010","journal-title":"Arch Intern Med"},{"key":"2022031220273979900_B8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"2022031220273979900_B12","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2022031220273979900_B13","first-page":"CD005270","article-title":"Long-term non-pharmacological weight loss interventions for adults with prediabetes","author":"Norris","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220273979900_B14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.psc.2011.08.006","article-title":"Behavioral treatment of obesity","volume":"34","author":"Butryn","year":"2011","journal-title":"Psychiatr Clin North Am"},{"key":"2022031220273979900_B15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031220273979900_B16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"2022031220273979900_B17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4158\/EP13263.RA","article-title":"New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach","volume":"19","author":"Garvey","year":"2013","journal-title":"Endocr Pract"},{"key":"2022031220273979900_B18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jdiacomp.2013.04.011","article-title":"New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)","volume":"27","author":"Henry","year":"2013","journal-title":"J Diabetes Complications"},{"key":"2022031220273979900_B19"},{"key":"2022031220273979900_B20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031220273979900_B21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2022031220273979900_B22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/j.1550-8528.1995.tb00158.x","article-title":"Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss","volume":"3","author":"Guare","year":"1995","journal-title":"Obes Res"},{"key":"2022031220273979900_B24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2337\/diacare.10.5.563","article-title":"Type II diabetic subjects lose less weight than their overweight nondiabetic spouses","volume":"10","author":"Wing","year":"1987","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031220273979900_B26","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031220273979900_B27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/oby.2006.84","article-title":"The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it","volume":"14","author":"Wadden","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"2022031220273979900_B28","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3309\/618511\/3309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3309\/618511\/3309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:25:42Z","timestamp":1647105942000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/12\/3309\/29099\/Weight-Loss-Therapy-in-Type-2-Diabetes-Effects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,8]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,8]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-0930","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,8]]}}}